Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
ProQR Therapeutics
company
About
ProQR Therapeutics is a biotech company focused on developments of drugs to treat genetic disorders.
- Leiden,Zuid-Holland,The Netherlands
- 101 - 250
- https://www.proqr.com/
Details
- Last Funding Type
- Post-IPO Equity
- Industries
- Biotechnology,Genetics,Health Care,Therapeutics
- Founded date
- Jan 1, 2012
- Number Of Employee
- 101 - 250
- Operating Status
- Active
- Stock Symbol
- nasdaq:PRQR
- Legal Name
- ProQR Therapeutics NV
ProQR Therapeutics is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. The company's main product candidates are QR-010, QR-110, and QR-313. Its product pipeline includes QRX-704, QRX-504, QRX-421, QRX-323 etc.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
9
$392.60M €46.70M
ProQR Therapeutics has raised a total of
$392.60M €46.70M
in funding over 2 rounds. Their latest funding was raised on
Dec 26, 2022 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 26, 2022 | Post-IPO Equity | — | 1 |
Eli Lilly
|
— | Detail |
| Mar 30, 2021 | Post-IPO Equity | $103.50M | — | — | — | Detail |
| Jul 14, 2020 | Post-IPO Debt | $30M | 1 |
Pontifax
|
— | Detail |
| Oct 15, 2019 | Post-IPO Equity | $57.50M | — | — | — | Detail |
| Dec 10, 2018 | Post-IPO Debt | €4.70M | — | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
3
3
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Eli Lilly
|
Yes | Post-IPO Equity |
|
Pontifax
|
Yes | Post-IPO Debt |
Sofinnova Partners
|
Yes | Series A |
Employee Profiles
Number of Employee Profiles
8
ProQR Therapeutics has 8 current employee profiles, including
Executive Dinko Valerio
Executive
Executive
Executive
Executive
Executive
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
